Natural Health Science News The latest news and top resources on natural health.

Stomach Acid – GERD

Posted May 2, 2017

A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD.

GERD; Stomach Acid Level/Pressure

Arts, J., R. Bisschops, K. Blondeau, R. Farre, R. Vos, L. Holvoet, P. Caenepeel, A. Lerut, and J. Tack. “A Double-Blind Sham-Controlled Study of the Effect of Radiofrequency Energy on Symptoms and Distensibility of the Gastro-Esophageal Junction in Gerd.” [In eng]. Am J Gastroenterol 107, no. 2 (Feb 2012): 222-30.

Alginate controls heartburn in patients with erosive and nonerosive reflux disease.

Antacid, GERD

Savarino, E., N. de Bortoli, P. Zentilin, I. Martinucci, L. Bruzzone, M. Furnari, S. Marchi, and V. Savarino. “Alginate Controls Heartburn in Patients with Erosive and Nonerosive Reflux Disease.” [In eng]. World J Gastroenterol 18, no. 32 (Aug 28 2012): 4371-8.

Alginate-antacid combinations: Raft formation and gastric retention studies.

GERD

Hampson, F. C., I. G. Jolliffe, A. Bakhtyari, G. Taylor, J. Sykes, L. M. Johnstone, and P. W. Dettmar. “Alginate-Antacid Combinations: Raft Formation and Gastric Retention Studies.” [In eng]. Drug Dev Ind Pharm 36, no. 5 (May 2010): 614-23.

Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.

GERD, Esohphageal adenocarcinoma

Renouf, D. J., R. Zhai, B. Sun, W. Xu, W. Y. Cheung, R. S. Heist, M. H. Kulke, et al. “Association of Mdm2 T309g and P53 Arg72pro Polymorphisms and Gastroesophageal Reflux Disease with Survival in Esophageal Adenocarcinoma.” [In eng]. J Gastroenterol Hepatol 28, no. 9 (Sep 2013): 1482-8.

Association of the CagA gene positive Helicobacter pylori and tissue levels of interleukin-17 and interleukin-8 in gastric ulcer patients.

H.Pylori

El-Fakhry, A. A., M. A. El-Daker, R. I. Badr, G. M. El-Nady, M. R. Mesbah, T. Youssef, M. Arafa, and M. M. El-Naggar. “Association of the Caga Gene Positive Helicobacter Pylori and Tissue Levels of Interleukin-17 and Interleukin-8 in Gastric Ulcer Patients.” [In eng]. Egypt J Immunol 19, no. 1 (2012): 51-62.

Circulating interleukin-27 levels in Helicobacter pylori-infected patients with gastric or duodenal ulcers, independent of the bacterial cytotoxin-associated gene A virulence factor.

H.Pylori

Jafarzadeh, A., M. Nemati, and M. T. Rezayati. “Circulating Interleukin-27 Levels in Helicobacter Pylori-Infected Patients with Gastric or Duodenal Ulcers, Independent of the Bacterial Cytotoxin-Associated Gene a Virulence Factor.” [In eng]. J Dig Dis 12, no. 4 (Aug 2011): 302-7.

Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection–the results of a multicentre, double-blind, randomized clinical trial (IMPACT study).

h.Pylori

Murakami, K., T. Okimoto, M. Kodama, J. Tanahashi, K. Mizukami, M. Shuto, H. Abe, T. Arita, and T. Fujioka. “Comparison of the Efficacy of Irsogladine Maleate and Famotidine for the Healing of Gastric Ulcers after Helicobacter Pylori Eradication Therapy: A Randomized, Controlled, Prospective Study.” [In eng]. Scand J Gastroenterol 46, no. 3 (Mar 2011): 287-92.

Distinguishing Menetrier’s disease from its mimics.

Stomach Acid Level/Pressure

Rich, A., T. Z. Toro, J. Tanksley, W. H. Fiske, C. D. Lind, G. D. Ayers, H. Piessevaux, M. K. Washington, and R. J. Coffey. “Distinguishing Menetrier’s Disease from Its Mimics.” [In eng]. Gut 59, no. 12 (Dec 2010): 1617-24.

Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans.

Antacid, H.Pylori

Celinski, K., P. C. Konturek, S. J. Konturek, M. Slomka, H. Cichoz-Lach, T. Brzozowski, and W. Bielanski. “Effects of Melatonin and Tryptophan on Healing of Gastric and Duodenal Ulcers with Helicobacter Pylori Infection in Humans.” [In eng]. J Physiol Pharmacol 62, no. 5 (Oct 2011): 521-6.

Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.

GERD

Haddad, I., J. Kierkus, E. Tron, A. Ulmer, P. Hu, S. Sloan, S. Silber, and G. Leitz. “Efficacy and Safety of Rabeprazole in Children (1-11 Years) with Gastroesophageal Reflux Disease.” [In eng]. J Pediatr Gastroenterol Nutr 57, no. 6 (Dec 2013): 798-807.

Emerging therapeutic options in GERD.

GERD

Woodland, P., G. Amarasinghe, and D. Sifrim. “Emerging Therapeutic Options in Gerd.” [In eng]. Best Pract Res Clin Gastroenterol 27, no. 3 (Jun 2013): 455-67.

Esophageal motility in children with suspected gastroesophageal reflux disease.

GERD, Stomach Acid Level/Pressure

Hoffman, I., T. De Greef, N. Haesendonck, and J. Tack. “Esophageal Motility in Children with Suspected Gastroesophageal Reflux Disease.” [In eng]. J Pediatr Gastroenterol Nutr 50, no. 6 (Jun 2010): 601-8.

Esophageal motor function of gastroesophageal reflux disease.

GERD, Stomach Acid Level/Pressure

Wang, H., Y. Tian, and Y. Ding. “[Esophageal Motor Function of Gastroesophageal Reflux Disease].” [In chi]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 32, no. 4 (Aug 2010): 465-9.

Esophageal mucosal metastasis from adenocarcinoma of the distal stomach.

GERD, Gastric Cancer

Ki, S. H., S. Jeong, I. S. Park, D. H. Lee, J. I. Lee, K. S. Kwon, H. G. Kim, and Y. W. Shin. “Esophageal Mucosal Metastasis from Adenocarcinoma of the Distal Stomach.” [In eng]. World J Gastroenterol 19, no. 23 (Jun 21 2013): 3699-702.

Gastric hyposecretion in esophageal squamous-cell carcinomas.

esophageal squamous cell carcinoma, Stomach Acid Level/Pressure

Iijima, K., T. Koike, Y. Abe, H. Yamagishi, N. Ara, K. Asanuma, K. Uno, et al. “Gastric Hyposecretion in Esophageal Squamous-Cell Carcinomas.” [In eng]. Dig Dis Sci 55, no. 5 (May 2010): 1349-55.

Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: The Swedish Adherence Register Analysis (SARA).

Landfeldt, E., A. Lang, S. Robbins, and O. Strom. “Gastrointestinal Tolerability and Patterns of Switching in Patients Treated for Primary Osteoporosis: The Swedish Adherence Register Analysis (Sara).” [In eng]. Calcif Tissue Int 89, no. 3 (Sep 2011): 234-45.

Global patterns of seasonal variation in gastrointestinal diseases.

GERD, colon cancer

Fares, A. “Global Patterns of Seasonal Variation in Gastrointestinal Diseases.” [In eng]. J Postgrad Med 59, no. 3 (Jul-Sep 2013): 203-7.

Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative study.

Antacid, H.Pylori

Song, K. H., Y. C. Lee, D. M. Fan, Z. Z. Ge, F. Ji, M. H. Chen, H. C. Jung, et al. “Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-Positive Gastric Ulcer Patients after Eradication Therapy: A Randomized Double-Blind, Multinational, Multi-Institutional Comparative Study.” [In eng]. Digestion 84, no. 3 (2011): 221-9.

Helicobacter pylori-associated hypochlorhydria in children, and development of iron deficiency.

H.Pylori, Stomach Acid Level/Pressure

Harris, P. R., C. A. Serrano, A. Villagran, M. M. Walker, M. Thomson, I. Duarte, H. J. Windle, and J. E. Crabtree. “Helicobacter Pylori-Associated Hypochlorhydria in Children, and Development of Iron Deficiency.” [In eng]. J Clin Pathol 66, no. 4 (Apr 2013): 343-7.

High-throughput screening of potassium-competitive acid blockers.

Antacid, GERD

Kondo, M., M. Kawamoto, A. Hasuoka, M. Kajino, N. Inatomi, and N. Tarui. “High-Throughput Screening of Potassium-Competitive Acid Blockers.” [In eng]. J Biomol Screen 17, no. 2 (Feb 2012): 177-82.

Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for zollinger-ellison syndrome.

Stomach Acid Level/Pressure

Shah, P., M. H. Singh, Y. X. Yang, and D. C. Metz. “Hypochlorhydria and Achlorhydria Are Associated with False-Positive Secretin Stimulation Testing for Zollinger-Ellison Syndrome.” [In eng]. Pancreas 42, no. 6 (Aug 2013): 932-6.

Improvement of clinical parameters in patients with gastroesophageal reflux disease after radiofrequency energy delivery.

Antacid, GERD

Liu, H. F., J. G. Zhang, J. Li, X. G. Chen, and W. A. Wang. “Improvement of Clinical Parameters in Patients with Gastroesophageal Reflux Disease after Radiofrequency Energy Delivery.” [In eng]. World J Gastroenterol 17, no. 39 (Oct 21 2011): 4429-33.

Long-Term Acid Inhibition: Benefits and Harms.

Antacid, Long Term Use, Stomach Acid Level/ Pressure

Tepes, B. “Long-Term Acid Inhibition: Benefits and Harms.” [In eng]. Dig Dis 29, no. 5 (2011): 476-81.

New immunological investigations on Helicobacter pylori-induced gastric ulcer in patients.

H.Pylori

Rahimi, H. R., M. Rasouli, A. Jamshidzadeh, S. Farshad, M. S. Firoozi, A. R. Taghavi, and S. Kiany. “New Immunological Investigations on Helicobacter Pylori-Induced Gastric Ulcer in Patients.” [In eng]. Microbiol Immunol 57, no. 6 (Jun 2013): 455-62.

Overlap of functional dyspepsia and GERD – Diagnostic and treatment implications.

Antacid, GERD

Quigley, E. M., and B. E. Lacy. “Overlap of Functional Dyspepsia and Gerd–Diagnostic and Treatment Implications.” [In eng]. Nat Rev Gastroenterol Hepatol 10, no. 3 (Mar 2013): 175-86.

Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: Mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.

Antacid, GERD

Sweis, R., E. Kaufman, A. Anggiansah, T. Wong, P. Dettmar, M. Fried, W. Schwizer, et al. “Post-Prandial Reflux Suppression by a Raft-Forming Alginate (Gaviscon Advance) Compared to a Simple Antacid Documented by Magnetic Resonance Imaging and Ph-Impedance Monitoring: Mechanistic Assessment in Healthy Volunteers and Randomised, Controlled, Double-Blind Study in Reflux Patients.” [In eng]. Aliment Pharmacol Ther 37, no. 11 (Jun 2013): 1093-102.